Toggle Nav
mobile icon
My Cart
Close
  • Menu
  • Setting
  • Home
  • Signaling Pathways

Signaling Pathways

Items 1-10 of 25

Page
per page
  1. Sorafenib Tosylate
    A8245 Sorafenib Tosylate
     1 Citation
    Target: Raf|VEGFR
    Summary: Raf kinases and tyrosine kinases inhibitor
      ≥31.85 mg/mL
  2. SP 600125
    A4604 SP 600125
     7 Citation
    Target: JNK
    Summary: JNK1/2/3 inhibitor
      insoluble in H2O; ≥11 mg/mL
  3. GDC-0879
    A5071 GDC-0879
     1 Citation
    Target: Raf
    Summary: B-Raf inhibitor,potent and selective
      insoluble in EtOH; insoluble in H2O; ≥16.7 mg/mL
  4. PD184352 (CI-1040)
    A1792 PD184352 (CI-1040)
    Target: MEK
    Summary: Selective MEK inhibitor
      ≥47.9 mg/mL
  5. SB202190 (FHPI)
    A1632 SB202190 (FHPI)
     5 Citation
    Target: p38
    Summary: P38 MAPK inhibitor
  6. U0126-EtOH
    A1337 U0126-EtOH
     10 Citation
    Target: MEK
    Summary: MEK1/2 inhibitor
      ≥21.33 mg/mL
  7. LY2228820
    A5566 LY2228820
     1 Citation
    Target: p38
    Summary: P38 MAP kinase inhibitor
      ≥30.65 mg/mL
  8. Pimasertib (AS-703026)
    A5573 Pimasertib (AS-703026)
    Target: MEK
    Summary: MEK1/2 inhibitor
      ≥21.55 mg/mL
  9. BIX 02189
    A5801 BIX 02189
    Target: MEK|ERK
    Summary: Selective MEK5 inhibitor
      ≥22.05 mg/mL
  10. MEK162 (ARRY-162, ARRY-438162)
    A1947 MEK162 (ARRY-162, ARRY-438162)
    Target: MEK
    Summary: MEK1/2 inhibitor,potent and selective
      insoluble in H2O; insoluble in EtOH; insoluble in DMSO

Items 1-10 of 25

Page
per page